FOLD Stock Overview
A biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Amicus Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$9.92 |
52 Week High | US$14.57 |
52 Week Low | US$9.02 |
Beta | 0.73 |
11 Month Change | 1.22% |
3 Month Change | -15.57% |
1 Year Change | -21.02% |
33 Year Change | 2.37% |
5 Year Change | -16.36% |
Change since IPO | -31.25% |
Recent News & Updates
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics: Too Cheap At Under $10 A Share
May 20Recent updates
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics: Too Cheap At Under $10 A Share
May 20Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 27Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Feb 29Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk
Dec 19Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Jul 06Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors
May 14Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
Mar 23We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt
Dec 06Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Aug 25Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding
Aug 10Amicus Therapeutics Q2 2022 Earnings Preview
Aug 03Is Amicus Therapeutics (NASDAQ:FOLD) Weighed On By Its Debt Load?
May 06Amicus Therapeutics: An Inflection Point In Growth
Apr 27Amicus: July 29 PDUFA Makes It A Hold
Apr 11Shareholder Returns
FOLD | US Biotechs | US Market | |
---|---|---|---|
7D | -1.7% | -0.7% | 0.07% |
1Y | -21.0% | 10.2% | 20.7% |
Return vs Industry: FOLD underperformed the US Biotechs industry which returned 10% over the past year.
Return vs Market: FOLD underperformed the US Market which returned 20.7% over the past year.
Price Volatility
FOLD volatility | |
---|---|
FOLD Average Weekly Movement | 5.4% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: FOLD has not had significant price volatility in the past 3 months.
Volatility Over Time: FOLD's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 517 | Brad Campbell | amicusrx.com |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. Fundamentals Summary
FOLD fundamental statistics | |
---|---|
Market cap | US$2.94b |
Earnings (TTM) | -US$147.07m |
Revenue (TTM) | US$423.49m |
6.9x
P/S Ratio-20.0x
P/E RatioIs FOLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FOLD income statement (TTM) | |
---|---|
Revenue | US$423.49m |
Cost of Revenue | US$43.95m |
Gross Profit | US$379.54m |
Other Expenses | US$526.61m |
Earnings | -US$147.07m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.50 |
Gross Margin | 89.62% |
Net Profit Margin | -34.73% |
Debt/Equity Ratio | 297.2% |
How did FOLD perform over the long term?
See historical performance and comparison